Outcome‐specific risk factors challenge universal dementia prevention priorities: Findings from the Egyptian Dementia Network Registry
Shimaa A. Heikal(American University in Cairo), Mohamed Salama(Mansoura University), Gharib Fawi(Sohag University), Sara Elfarrash(Mansoura University), Samer Salama(Mansoura University), Ahmed Qayaty(Beni-Suef University), Mai Othman(American University in Cairo), Eman M. Khedr(Assiut University Hospitals), Hany I. Hassanin(Ain Shams University), Nesma G. Elsheikh(Ain Shams University), Heba M. Tawfik(Ain Shams University), Eman M. Ali(Beni-Suef University), Sara A. Moustafa(American University in Cairo), Amna Ibrahim(Beni-Suef University)
Cited by 0
Related Papers
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
|Clinical Cancer Research|2015|532
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
|Clinical Cancer Research|2015|377
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
|Clinical Cancer Research|2014|350
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
|Journal of Clinical Oncology|2019|348